| 29.1 0.1 (0.34%) | 06-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 35.64 | 1-year : | 39.7 |
| Resists | First : | 30.52 | Second : | 33.99 |
| Pivot price | 27.66 |
|||
| Supports | First : | 24.9 | Second : | 20.72 |
| MAs | MA(5) : | 28.7 |
MA(20) : | 27.7  |
| MA(100) : | 23.28 |
MA(250) : | 22.39 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 76.3 |
D(3) : | 74.2 |
| RSI | RSI(14): 56 |
|||
| 52-week | High : | 37.26 | Low : | 14.64 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ NGNE ] has closed below upper band by 12.0%. Bollinger Bands are 38% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.8 - 29.91 | 29.91 - 30 |
| Low: | 27.91 - 28.05 | 28.05 - 28.15 |
| Close: | 28.89 - 29.11 | 29.11 - 29.28 |
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Mon, 08 Jun 2026
Number of shareholders of Neurogene Inc. – NASDAQ:NGNE - TradingView
Mon, 08 Jun 2026
Neurogene (NGNE) Completes Dosing in Key Trial for NGN-401 - GuruFocus
Mon, 08 Jun 2026
Neurogene completes dosing in Embolden trial, doses 25 participants; topline data due 2H 2027 - TradingView
Mon, 08 Jun 2026
Neurogene (NGNE) finishes dosing in NGN-401 Embolden Rett registrational trial - Stock Titan
Mon, 08 Jun 2026
25 girls receive Neurogene’s one-time gene therapy in key Rett syndrome trial - Stock Titan
Fri, 05 Jun 2026
NGNE News | NEUROGENE INC (NASDAQ:NGNE) - ChartMill
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 8.8 (%) |
| Held by Institutions | 110.3 (%) |
| Shares Short | 3,600 (K) |
| Shares Short P.Month | 4,010 (K) |
| EPS | -4.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24 % |
| Return on Equity (ttm) | -37.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -5.21 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -6.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -83 (M) |
| Levered Free Cash Flow | -48 (M) |
| PE Ratio | -6.4 |
| PEG Ratio | 0 |
| Price to Book value | 1.7 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|